Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug AZD0780 aims to lower blood pressure in heart patients

NCT ID NCT06692764

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called AZD0780 in 202 people with heart disease or related risks and high LDL cholesterol. Participants took either the drug or a placebo for 4 weeks, and researchers measured changes in blood pressure using a 24-hour monitor. The goal was to see if AZD0780 can safely lower blood pressure in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD0780
What this could lead to
If successful, AZD0780 could offer a new way to lower blood pressure in people with heart disease and high cholesterol, potentially reducing heart attack and stroke risk.
What could go wrong
This is a small, early Phase II study with only 202 participants. Results may not apply to everyone, and the drug may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

202 people

The number who actually took part.

Started

Oct 2024

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant must be ≥ 18 years of age at the time of signing the informed consent. 2. Participants with a history of ASCVD defined as myocardial infarction, stroke, or symptomatic peripheral arterial disease, or with risk factors hereof. 3. Participants with a fasting serum LDL-C ≥ 70 mg/dL (1.8 mmol/L) at screening. 4. Should be receiving stable SoC therapy for their comorbidities for at least 4 weeks prior to screening. There should be no planned medication or dose changes during study participation. 5. Body mass index ≥ 19.0 kg/m2. 6. Sex: males and females (females of non-childbearing potential). Exclusion Criteria 1. eGFR \< 45 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (2021) at screening. 2. History or presence of gastrointestinal, hepatic, or renal disease, or any other conditions known to interfere with absorption, distribution, metabolism, or excretion of drugs. 4\. Poorly controlled type 2 diabetes mellitus, defined as HbA1c \> 10% at screening. 5\. Participants with history of coronary artery bypass graft surgery ≤ 6 months prior to screening or percutaneous coronary intervention ≤ 3 months prior to screening. 6\. Heart failure with New York Heart Association Class III to IV. 9. Low-density protein or plasma apheresis within 12 months prior to Period 1 Day -1. 10\. Uncontrolled hypertension defined as average of triplicate seated SBP \> 160 mmHg or DBP \> 90 mmHg at screening. 11\. Pulse rate after 10 minutes seated rest \< 50 or \> 100 bpm at screening. 12. Any laboratory values with the following deviations at screening; test may be repeated at the discretion of the investigator if abnormal: (a) Any positive result on screening for hepatitis B, hepatitis C, or HIV; (b) ALT \> 1.5 × ULN; (c) AST \> 1.5 × ULN; (d) TBL \> ULN; (e) Haemoglobin \< 12 g/dL in males or \< 11 g/dL in females; (f) Potassium \< lower limit of normal. 13. Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG and any clinically important abnormalities in the 12-lead ECG as judged by the investigator, including: 1. family history of long QT syndrome; 2. PR interval prolongation \> 240 ms; 3. QTcF \> 450 ms; (\> 470 ms in participants with bundle branch block) 4. any intermittent or persistent high degree atrioventricular-block grade II-III and sinus node dysfunction with significant sinus pause untreated with pacemaker; and cardiac tachyarrhythmias requiring treatment. 18\. Lomitapide within 12 months prior to Period 1 Day -1. 19. Current or previous treatment with drugs for reduction or inhibition of PCSK9 (approved or investigational, eg, evolocumab, alirocumab, or inclisiran) within 12 months prior to Period 1 Day -1. 20\. Fibrate therapy and derivatives are prohibited. 21. Receiving or has received within 14 days of screening, medication that contains a black box warning for significant QT prolongation. A list of prohibited medications can be found in Appendix G. 22\. Nutraceuticals or homeopathic treatments which may have an impact on BP. 26. Participants working 3rd shift or night shifts based on potential changes in circadian rhythm. 27\. Participants with sleep disorders that would affect ABPM measurements, in the investigator's opinion. 28\. Participant arm circumference not appropriate for available ABPM cuff circumference, or participant has a medical device (eg, continuous glucose monitor) that prevents use of the ABPM device, in the opinion of the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerotic cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerotic cardiovascular disease

Contacts and locations

Locations

  • Research Site

    Inglewood, California, 90301, United States

  • Research Site

    Northridge, California, 91325, United States

  • Research Site

    Pomona, California, 91767, United States

  • Research Site

    Boca Raton, Florida, 33434, United States

  • Research Site

    Hialeah, Florida, 33012, United States

  • Research Site

    Jacksonville, Florida, 32216, United States

  • Research Site

    Miami, Florida, 33122, United States

  • Research Site

    Miami, Florida, 33165, United States

  • Research Site

    Miami, Florida, 33173, United States

  • Research Site

    Miami, Florida, 33174, United States

  • Research Site

    Ocala, Florida, 34474, United States

  • Research Site

    Port Orange, Florida, 32127, United States

  • Research Site

    Tamarac, Florida, 33321, United States

  • Research Site

    Chicago, Illinois, 60621, United States

  • Research Site

    Potomac, Maryland, 20854, United States

  • Research Site

    New Bedford, Massachusetts, 02740, United States

  • Research Site

    New Windsor, New York, 12553, United States

  • Research Site

    Beavercreek, Ohio, 45431, United States

  • Research Site

    Horsham, Pennsylvania, 19044, United States

  • Research Site

    Spartanburg, South Carolina, 29303, United States

  • Research Site

    Austin, Texas, 78704, United States

  • Research Site

    Dallas, Texas, 75230, United States

  • Research Site

    El Paso, Texas, 79905, United States

  • Research Site

    Hurst, Texas, 76054, United States

  • Research Site

    Mesquite, Texas, 75149, United States

  • Research Site

    Paris, Texas, 75462, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.